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Abstract 
Background 
The 2017 American guidelines on hypertension management recommend introduction of 
antihypertensive treatment for patients with new stage 1 hypertension thresholds (130-139/80-89 
mm Hg) and with a cardiovascular disease or related condition. We compared the Swiss 
population and economic impact of antihypertensive treatment of the 2017 American guidelines 
with the 2013 European guidelines. 
Methods 
Analyses were based on 4,438 participants (aged 45-85 years; 2,448 women) of the 
CoLaus|PsyCoLaus study. Participants eligible to antihypertensive treatment according to the 
guidelines were sex- and age-standardized using the Swiss population for year 2016. In addition, 
we estimated the population-wide annual costs of antihypertensive treatment. 
Results 
Individuals eligible to an antihypertensive treatment were 40.3% (95% CI, 38.5 to 42.1) and 31.3% 
(29.7 to 32.9) according to the American and European guidelines, respectively. That difference 
would translate into ~250,000 additional individuals eligible to an antihypertensive treatment, 
corresponding to an additional annual cost of 72.5 million CHF (63.0 million Euros). 
Conclusion 
The 2017 American guidelines on management of hypertension substantially increase the number 
of individuals eligible to an antihypertensive treatment compared to the European guidelines. 
While implementation of the 2017 American guidelines is expected to lead to costs reduction by 
preventing cardiovascular diseases, that reduction might be mitigated by the costs incurred by 
antihypertensive treatments in a larger proportion of the population. 
  
Introduction 
The American College of Cardiology (ACC) and the American Heart Association (AHA) 
released in 2017 guidelines for hypertension management, defining stage 1 hypertension based on 
lower thresholds (130-139/80-89 mm Hg).1 Antihypertensive treatment is recommended for 
patients above those thresholds with previous cardiovascular disease (CVD) or related risk. 
Conversely, the 2013 European Society of Hypertension and European Society of Cardiology 
(ESH/ESC) guidelines for hypertension management define stage 1 hypertension, and the 
threshold to introduce an antihypertensive medication, based on a SBP of 140-159 mm Hg or a 
DBP of 90-99 mm Hg.2 From a public health perspective, there exists an interest in managing a 
larger number of individuals to prevent the deleterious effects of hypertension.3 However, 
aggressive BP treatment is also associated with adverse events and higher costs.4 Hence, using 
data from the population-based CoLaus|PsyCoLaus study, we contrasted the population impact of 
the 2017 ACC/AHA and 2013 ESH/ESC guidelines. 
Methods 
Data were collected between 2014 and 2017 in 4,438 participants (2,448 women) aged 45-
85 years.5 Participants eligible to antihypertensive treatments were selected according to 
guidelines. Participants on BP-lowering treatment had their SBP and DBP levels increased by 10 
and 5 mm Hg, respectively.6 For the 2017 ACC/AHA approach, we stratified individuals according 
to their ten-year CVD risk, using original SBP and DBP values.7 For the 2013 ESH/ESC approach, we 
considered that an antihypertensive drug would be introduced for all participants with stage 1 
hypertension, assuming several months of lifestyle changes. Assuming full compliance with the 
guidelines, results from the CoLaus|PsyCoLaus study were extrapolated to the Swiss population of 
2016, aged 45-85 years (same age group), as reported by the Swiss Federal Statistical Office 
(www.ofs.ch). Furthermore, we performed sex- and age-standardization.  Population-wide annual 
cost of antihypertensive treatment was estimated based on an annual cost of CHF 281.- per 
hypertensive patient (EUR 242.-, exchange rate valid as of March 5 2018) as computed by the 
Swiss Health Observatory (Obsan Rapport 50, www.obsan.admin.ch).  
Results 
Individuals eligible to an antihypertensive treatment were 40.3% (95% CI, 38.5 to 42.1) and 
31.3% (29.7 to 32.9) according to 2017 ACC/AHA and 2013 ESH/ESC guidelines, respectively (Table 
1). For those already taking antihypertensive drugs, 53.8% and 38.2% should intensify their 
treatment to meet the 2017 ACC/AHA and 2013 ESH/ESC guidelines, respectively. After 
extrapolation to the Swiss population, implementation of the 2017 ACC/AHA guidelines would 
translate into ~250,000 additional individuals eligible to an antihypertensive treatment, leading to 
an additional cost of 72.5 million CHF (62.2 million Euros). 
Discussion 
The 2017 ACC/AHA guidelines on hypertension management substantially increase the 
number of individuals eligible to an antihypertensive treatment compared to the prevailing 
European guidelines, especially  for individuals >65 years, in both sexes, and despite the selection 
of high-risk individuals. Other consequences related to implementation of the 2017 ACC/AHA 
guidelines (e.g. expected reduction of CVD; potential increased risk of CVD in treated individuals with 
DBP ≤70 mm Hg and/or pulse pressure ≥60 mm Hg8, 9) were not considered and may influence global 
costs. We thus recommend a careful evaluation of the cost-effectiveness of the 2017 ACC/AHA 
guidelines before any implementation. 
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Table 1 Population impact and annual costs of blood pressure-lowering treatments according to 2013 ESH/ESC and 2017 
ACC/AHA guidelines 
 
 2016 Swiss population Population eligible to BP-lowering treatment (%) Annual 
cost of 
treatment 
(in mio 
Euros) 
 
Total Men Women Total Men Women 
2013 ESH/ESC guidelines  
 Overall 3,681,718 1,797,002 1,884,716 1,151,993 (31.3 %) 657,131 (36.6 %) 509,814 (27.0 %) 277.8 
 Age groups       
 45-55 1,313,720 663,466 650,254 221,864 (16.9 %) 144,548 (21.8 %) 78,112 (12.0 %) 53.5 
 55-65 1,056,520 528,645 527,875 309,133 (29.3 %) 193,646 (36.6 %) 120,617 (22.8 %) 74.5 
 65-75 814,608 390,285 424,323 347,927 (42.7 %) 196,818 (50.4 %) 159,646 (37.6 %) 83.9 
 75-85 496,870 214,606 282,264 273,070 (55.0 %) 122,119 (56.9 %) 151,439 (53.7 %) 65.8 
2017 ACC/AHA guidelines  
 Overall 3,681,718 1,797,002 1,884,716 1,409,912 (38.3 %) 834,440 (46.4 %) 604,082 (32.1 %) 340.0 
 Age groups       
 45-55 1,313,720 663,466 650,254 232,135 (17.7 %) 150,788 (22.7 %) 82,169 (12.6 %) 56.0 
 55-65 1,056,520 528,645 527,875 335,717 (31.8 %) 219,792 (41.6 %) 122,745 (23.3 %) 80.9 
 65-75 814,608 390,285 424,323 460,431 (56.5 %) 291,457 (74.7 %) 189,055 (44.6 %) 111.0 
 75-85 496,870 214,606 282,264 381,630 (76.8 %) 172,403 (80.3 %) 210,112 (74.4 %) 92.0 
Estimates of the Swiss population eligible to a BP-lowering treatment are derived from CoLaus|PsyCoLaus data (i.e. percentage). Overall 
percentages were derived after sex- and age-standardization. Annual costs were first computed in Swiss francs and then converted into Euros. 
ACC, American College of Cardiology; AHA, American Heart Association; ESH, European Society of Hypertension; ESC, European Society of 
Cardiology. 
 
  
 
